NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Follow-Up Questions
Qui est le CEO de Neogenomics Inc ?
Mr. Antony Zook est le Chief Executive Officer de Neogenomics Inc, il a rejoint l'entreprise depuis 2023.
Quelle est la performance du prix de l'action NEO ?
Le prix actuel de NEO est de $10.15, il a increased de 0.56% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Neogenomics Inc ?
Neogenomics Inc appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Neogenomics Inc ?
La capitalisation boursière actuelle de Neogenomics Inc est de $1.3B
Est-ce que Neogenomics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 12 analystes ont établi des notations d'analystes pour Neogenomics Inc, y compris 3 achat fort, 6 achat, 9 maintien, 1 vente et 3 vente forte
